(PQD1) Evolution of vemurafenib resistance in circulating melanoma cells
(PQD1) Evolution of vemurafenib resistance in circulating melanoma cells
批准号:
8851544
负责人:
CARL D NOVINA
金额:
$69.26万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-05-21 至 2018-04-30
关键词:
BRAF geneBioinformaticsBiopsyBlood CirculationCancerousCellsCessation of lifeClinical DataDataDevelopmentDiseaseDistant MetastasisDoseDrug TargetingDrug resistanceEmerging TechnologiesEnrollmentEvolutionFutureGene Expression ProfileGenerationsGenesGeneticGenetic ProgrammingGoalsHealthHumanIndividualLinkLiquid substanceMEK inhibitionMalignant NeoplasmsMapsMelanoma CellMetastatic MelanomaMethodsMolecularMonitorMutationNatureNeoplasm Circulating CellsNeoplasm MetastasisOncogenesOutcomeOutputPathway AnalysisPathway interactionsPatientsPharmaceutical PreparationsPharmacotherapyPopulationPrimary NeoplasmProductionRegimenResistanceResistance developmentResourcesRoleSamplingSeedsSiteSkin CancerSourceStagingSurvival RateTechnologyTherapeuticTimeTreatment EfficacyTreatment FailureUnited StatesVariantVirulencebasecancer cellcancer diagnosiscancer stem cellcancer typeclinical decision-makingclinical efficacydesignexperienceinhibitor/antagonistinnovationkinase inhibitormelanomamutantnon-drugnovelnovel therapeuticsoutcome forecastoverexpressionpressureprogramsresistance mechanismresponsesmall moleculetargeted treatmenttechnology developmenttime usetranscriptome sequencingtumortumorigenesis
中文摘要
描述(申请人提供):黑色素瘤是美国第六大常见癌症,每年导致近8000人死亡。虽然在早期发现黑色素瘤是可以治疗的,但一旦疾病进展并转移,几乎所有人都会在5年内死亡,因此显然需要新的治疗方案。循环肿瘤细胞(CTCs)是从原发或转移性肿瘤中脱落的癌细胞,最终形成新的癌灶。在黑色素瘤中,CTCs被发现与转移性疾病的大部分侵袭性有关,包括对分子靶向治疗的抵抗。由于单个CTCs的毒力不同,我们假设单个CTC中独特的基因表达特征是耐药的来源。具体地说,我们假设BRAF抑制剂维莫拉非尼对黑色素瘤CTCs施加选择性压力,从而导致耐药性。要弄清维莫拉非尼耐药的潜在机制,需要对耐药演变过程中的单个CTC进行全面分析。我们最近的技术进步到了这样一个地步,我们可以强有力地分离罕见的黑色素瘤CTCs,并通过单细胞RNA-SEQ在转录水平上描述单个CTCs。通过我们的创新方法,我们可以在黑色素瘤CTC中识别出不同的遗传程序,每个程序都具有获得对分子靶向治疗的耐药性的独特潜力。我们建议精确地注释单个CTC中特定的基因表达特征以适应维莫拉非尼耐药的演变。黑色素瘤具有遗传异质性和临床可获得性,因此是一种最佳的癌症类型,可用于开发分析方法来评估异质性转录输出对耐药性演变的影响。我们的调查团队非常适合进行所需的技术开发和数据生成。从历史上看,黑色素瘤CTCs很难分离,因此是研究的一个挑战。然而,我们已经克服了这一技术障碍,最近确定了从血液中收集黑色素瘤CTCs的最佳条件。对于这项建议,我们寻求利用我们的经验、资源和能力来开发和实施RNA-seq从维莫拉非尼治疗前后黑色素瘤患者的单个CTC中分离出来的转录图谱。因此,我们将定义对维莫拉非尼治疗的反应的转录输出,通过实验验证它们在建立维莫拉非尼耐药性中的作用,从而确定关键基因作为新型维莫拉非尼耐药治疗的潜在靶点。
英文摘要
DESCRIPTION (provided by applicant): Melanoma is the sixth most common cancer in the United States, causing almost 8000 deaths annually. While melanoma is treatable when caught in the early stages, once the disease has progressed and becomes metastatic it is almost universally fatal within 5 years, so new therapeutic options are clearly needed. Circulating tumor cells (CTCs) are cancer cells shed from a primary or metastatic tumor and eventually seed new cancerous sites. In melanoma, CTCs have been found to be responsible for much of the aggressive nature of metastatic disease, including resistance to molecularly-targeted therapies. Because the virulence of individual CTCs varies, we hypothesize that unique gene expression signature in individual CTCs is the source of drug resistance. Specifically, we hypothesize that the BRAF inhibitor vemurafenib imposes a selective pressure on melanoma CTCs which results in resistance. Unraveling the underlying mechanisms of vemurafenib resistance will require comprehensive analysis of individual CTCs during the evolution of resistance. We recently advanced technology to the point where we can robustly isolate rare melanoma CTCs and transcriptionally profile individual CTCs by single cell RNA-seq. With our innovative approaches, we can identify distinct genetic programs in melanoma CTC each with unique potential to acquire resistance to molecularly-targeted therapies. We propose to precisely annotate specific gene expression signatures in individual CTCs to the evolution of vemurafenib resistance. Melanomas are both genetically heterogeneous and clinically accessible and therefore represent an optimal cancer type for the development of analytic methods to assess the effects heterogeneous transcriptional outputs on the evolution of drug resistance. Our investigative team is ideally suited to carry out the technology development and data generation required. Historically, melanoma CTCs have been difficult to isolate and therefore a challenge to study. However, we have overcome this technical hurdle and recently determined optimal conditions for collecting melanoma CTCs from the bloodstream. For this proposal, we seek to leverage our experience, resources and capabilities to develop and implement transcriptional profiling by RNA-seq from individual CTCs isolated from melanoma patients before and after vemurafenib treatment. We will thus define transcriptional outputs in response to vemurafenib treatment, experimentally validate their roles in establishing vemurafenib resistance and thereby identify key genes as potential targets for novel vemurafenib-resistance therapy.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Lnc'ing White Fat to Brown Fat Thermogenesis
-
批准号:10064214
-
项目类别:
-
资助金额:$88.5万
-
财政年份:2020
-
负责人:CARL D NOVINA
-
依托单位:
Defining LncRNA Function in normal and Shwachman Diamond Syndrome Myelopoiesis
-
批准号:10320386
-
项目类别:
-
资助金额:$44.13万
-
财政年份:2019
-
负责人:CARL D NOVINA
-
依托单位:
Engineering epigenetic therapy for sickle cell disease
-
批准号:8752559
-
项目类别:
-
资助金额:$86.5万
-
财政年份:2014
-
负责人:CARL D NOVINA
-
依托单位:
(PQD1) Evolution of vemurafenib resistance in circulating melanoma cells
-
批准号:8687169
-
项目类别:
-
资助金额:$60.31万
-
财政年份:2014
-
负责人:CARL D NOVINA
-
依托单位:
Engineering epigenetic therapy for sickle cell disease
-
批准号:8930980
-
项目类别:
-
资助金额:$86.5万
-
财政年份:2014
-
负责人:CARL D NOVINA
-
依托单位:
Dysregulated microRNA function in diamond blackfan anemia
-
批准号:8439603
-
项目类别:
-
资助金额:$34.77万
-
财政年份:2013
-
负责人:CARL D NOVINA
-
依托单位:
Dysregulated microRNA function in diamond blackfan anemia
-
批准号:8734422
-
项目类别:
-
资助金额:$34.58万
-
财政年份:2013
-
负责人:CARL D NOVINA
-
依托单位:
Dysregulated microRNA function in diamond blackfan anemia
-
批准号:9115159
-
项目类别:
-
资助金额:$34.77万
-
财政年份:2013
-
负责人:CARL D NOVINA
-
依托单位:
Analysis of cap-dependent translational repression by microRNAs in oncogensis
-
批准号:8700331
-
项目类别:
-
资助金额:$31.7万
-
财政年份:2011
-
负责人:CARL D NOVINA
-
依托单位:
Analysis of cap-dependent translational repression by microRNAs in oncogensis
-
批准号:8895074
-
项目类别:
-
资助金额:$32.68万
-
财政年份:2011
-
负责人:CARL D NOVINA
-
依托单位:
Analysis of cap-dependent translational repression by microRNAs in oncogensis
-
批准号:8508194
-
项目类别:
-
资助金额:$30.72万
-
财政年份:2011
-
负责人:CARL D NOVINA
-
依托单位:
Analysis of cap-dependent translational repression by microRNAs in oncogensis
-
批准号:8320147
-
项目类别:
-
资助金额:$32.68万
-
财政年份:2011
-
负责人:CARL D NOVINA
-
依托单位:
Analysis of cap-dependent translational repression by microRNAs in oncogensis
-
批准号:8187439
-
项目类别:
-
资助金额:$32.68万
-
财政年份:2011
-
负责人:CARL D NOVINA
-
依托单位:
A B-CELL SPECIFIC COFACTOR OF NUCLEOSOME REMODELING
-
批准号:6510063
-
项目类别:
-
资助金额:$4.81万
-
财政年份:2002
-
负责人:CARL D NOVINA
-
依托单位:
A B-CELL SPECIFIC COFACTOR OF NUCLEOSOME REMODELING
-
批准号:6372930
-
项目类别:
-
资助金额:$4.2万
-
财政年份:2001
-
负责人:CARL D NOVINA
-
依托单位:
A B-CELL SPECIFIC COFACTOR OF NUCLEOSOME REMODELING
-
批准号:6137099
-
项目类别:
-
资助金额:$3.75万
-
财政年份:2001
-
负责人:CARL D NOVINA
-
依托单位:
海外基金